IN2014DN01992A - - Google Patents

Info

Publication number
IN2014DN01992A
IN2014DN01992A IN1992DEN2014A IN2014DN01992A IN 2014DN01992 A IN2014DN01992 A IN 2014DN01992A IN 1992DEN2014 A IN1992DEN2014 A IN 1992DEN2014A IN 2014DN01992 A IN2014DN01992 A IN 2014DN01992A
Authority
IN
India
Prior art keywords
methyl
aminosulfonyl
thiazol
pyridinyl
phenyl
Prior art date
Application number
Inventor
Wilfried Schwab
Alexander Birkmann
Kerstin Paulus
Kurt Vögtli
Dieter Haag
Stephan Maas
Kristian Ruepp
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of IN2014DN01992A publication Critical patent/IN2014DN01992A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to the crystalline mesylate monohydrate salt of N [5 (aminosulfonyl) 4 methyl 1 3 thiazol 2 yl] N methyl 2 [4 (2 pyridinyl)phenyl]acet amide in a definite particle size distribution and a specific surface area range which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions as well as to pharmaceutical compositions containing said N [5 (aminosulfonyl) 4 methyl 1 3 thiazol 2 yl] N methyl 2 [4 (2 pyridinyl)phenyl]acetamide mesylate monohydrate having the afore mentioned particle size distribution and specific surface area range.
IN1992DEN2014 2011-09-26 2012-09-26 IN2014DN01992A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11007803A EP2573085A1 (en) 2011-09-26 2011-09-26 N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
PCT/EP2012/068958 WO2013045491A1 (en) 2011-09-26 2012-09-26 N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations.

Publications (1)

Publication Number Publication Date
IN2014DN01992A true IN2014DN01992A (en) 2015-05-15

Family

ID=46889071

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1992DEN2014 IN2014DN01992A (en) 2011-09-26 2012-09-26

Country Status (11)

Country Link
US (5) US9119786B2 (en)
EP (1) EP2573085A1 (en)
JP (1) JP6043356B2 (en)
KR (1) KR20140066705A (en)
CN (1) CN103842360B (en)
AU (1) AU2012314473B2 (en)
IN (1) IN2014DN01992A (en)
MX (1) MX364094B (en)
RU (1) RU2606628C2 (en)
WO (1) WO2013045491A1 (en)
ZA (1) ZA201401774B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
CN105101963A (en) 2013-02-12 2015-11-25 艾库里斯有限及两合公司 Helicase-primase inhibitors for use in a method of treating alzheimer's disease
AU2015320358B2 (en) * 2014-09-26 2020-05-14 Millendo Therapeutics, Inc. Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4-(dimethylamino)phenyl)cyclopentyl) methyl)urea hydrochloride and compositions, methods and kits related thereto
EP3744318A1 (en) * 2015-08-27 2020-12-02 Grindeks, A Joint Stock Company Pharmaceutical composition capable of the incorporation of lenalidomide in various crystalline modifications
PL3544976T3 (en) * 2016-11-28 2021-11-02 Aicuris Gmbh & Co. Kg N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide free base hemihydrate, methods of manufacture and uses thereof
TW201825095A (en) 2016-11-28 2018-07-16 德商艾庫里斯抗感染治療有限公司 Topical pharmaceutical formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide
HUE054845T2 (en) 2016-11-28 2021-10-28 Aicuris Gmbh & Co Kg A maleate salt of the free base of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, pharmaceutical formulations, methods of manufacture and uses thereof for the treatment of herpes viruses
NZ760339A (en) 2017-06-28 2023-06-30 Aicuris Gmbh & Co Kg Intravaginally applicable devices comprising antiviral compounds
TW202038947A (en) 2018-11-28 2020-11-01 德商創新分子有限責任公司 Helicase primase inhibitors for treating cancer in a combination therapy with oncolytic viruses
WO2024047507A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. A novel crystalline form of pritelivir
WO2024047506A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. A novel crystalline form of pritelivir
WO2024047508A1 (en) 2022-08-29 2024-03-07 Assembly Biosciences, Inc. Pharmaceutical compositions for herpes virus

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3720757A1 (en) 1987-06-24 1989-01-05 Bayer Ag DHP COAT TABLET
US6355684B1 (en) * 1990-10-11 2002-03-12 Meryl J. Squires Antimicrobial treatment for herpes simplex virus and other infectious diseases
US6348503B1 (en) 1996-02-12 2002-02-19 Meryl J. Squires Method and topical treatment composition for herpesvirus hominis
US9662360B2 (en) 2008-10-09 2017-05-30 Meritus Corporation Treatment of herpes, pseudomonas, staph, and hepatitis
DOP2000000109A (en) * 1999-12-23 2002-08-30 Gerald Kleymann THIAZOLILAMIDE DERIVATIVES
WO2001096874A1 (en) * 2000-06-15 2001-12-20 Bayer Aktiengesellschaft Method for identifying compounds with anti-herpes activity
DE10129716A1 (en) 2001-06-22 2003-01-02 Bayer Ag Combination preparation useful as antiviral agent effective against herpes viruses, especially herpes simplex, contains acetylsalicylic acid and 5-sulfonyl-2-phenylacetamido-thiazole derivative
DE10129717A1 (en) 2001-06-22 2003-01-02 Bayer Ag Combination preparation containing nucleoside compound and 5-sulfonyl-2-phenylacetamido-thiazole derivative, useful as antiviral agent effective againts herpes viruses, especially herpes simplex
DE10129714A1 (en) * 2001-06-22 2003-01-02 Bayer Ag Topical application of thiazolylamides
DE10131128A1 (en) * 2001-06-28 2003-01-16 Bayer Ag New 5-aminosulfonyl-2-phenylacetamido-thiazole derivatives, useful as antiviral medicaments effective against herpes viruses, especially herpes simplex
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
DE102005014248A1 (en) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmaceutical preparation of N- [5- (aminosulfonyl) -4-methyl-1,3-thiazol-2-yl] -N-methyl-2- [4- (2-pyridinyl) phenyl] acetamide
JP2007314516A (en) 2006-04-25 2007-12-06 Daiichi Sankyo Co Ltd Pharmaceutical containing benzene compound which has two or more substituents
AU2007257841A1 (en) 2006-06-09 2007-12-21 Icos Corporation Substituted phenyl acetic acids as DP-2 antagonists
AR070127A1 (en) 2008-01-11 2010-03-17 Novartis Ag PIRROLO - PIRIMIDINAS AND PIRROLO -PIRIDINAS
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP2573085A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
CN105101963A (en) * 2013-02-12 2015-11-25 艾库里斯有限及两合公司 Helicase-primase inhibitors for use in a method of treating alzheimer's disease
AU2015320358B2 (en) 2014-09-26 2020-05-14 Millendo Therapeutics, Inc. Solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4-(dimethylamino)phenyl)cyclopentyl) methyl)urea hydrochloride and compositions, methods and kits related thereto
PL3544976T3 (en) 2016-11-28 2021-11-02 Aicuris Gmbh & Co. Kg N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide free base hemihydrate, methods of manufacture and uses thereof
HUE054845T2 (en) 2016-11-28 2021-10-28 Aicuris Gmbh & Co Kg A maleate salt of the free base of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide, pharmaceutical formulations, methods of manufacture and uses thereof for the treatment of herpes viruses
KR102335327B1 (en) 2017-04-28 2021-12-03 현대자동차 주식회사 Water cooled egr cooler
NZ760339A (en) 2017-06-28 2023-06-30 Aicuris Gmbh & Co Kg Intravaginally applicable devices comprising antiviral compounds

Also Published As

Publication number Publication date
ZA201401774B (en) 2015-12-23
MX364094B (en) 2019-04-12
US20150366849A1 (en) 2015-12-24
CN103842360B (en) 2016-06-22
USRE49697E1 (en) 2023-10-17
US20140065224A1 (en) 2014-03-06
CN103842360A (en) 2014-06-04
US20160008341A1 (en) 2016-01-14
MX2014003623A (en) 2014-05-30
RU2606628C2 (en) 2017-01-10
US9592225B2 (en) 2017-03-14
JP2014527995A (en) 2014-10-23
US9119786B2 (en) 2015-09-01
RU2014116621A (en) 2015-11-10
JP6043356B2 (en) 2016-12-14
US20170348297A1 (en) 2017-12-07
AU2012314473B2 (en) 2015-09-17
KR20140066705A (en) 2014-06-02
WO2013045491A1 (en) 2013-04-04
AU2012314473A1 (en) 2014-02-06
EP2573085A1 (en) 2013-03-27
US10137117B2 (en) 2018-11-27
US9889124B2 (en) 2018-02-13

Similar Documents

Publication Publication Date Title
IN2014DN01992A (en)
IN2014DN01993A (en)
MD4490C1 (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
MX2014005635A (en) 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolin amide derivatives as orexin receptor antagonists.
MY172924A (en) Neprilysin inhibitors
IN2014CN04530A (en)
EP2797881A4 (en) Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same
SI2785711T1 (en) 2-(phenyl or pyrid-3-yl)aminopyrimidine derivatives as kinase lrrk2 modulators for the treatment of parkinson's disease
SI2318004T1 (en) Pharmaceutical compositions containing the crystalline form y of posaconazole
SG195106A1 (en) Trpv4 antagonists
MY176244A (en) Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
PH12016500322A1 (en) Amide derivatives as lysophosphatidic acid receptor antagonists
PH12015502632A1 (en) Cxcr7 receptor modulators
ZA201500362B (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
IL220707A (en) 2-(phenyl/heteroaryl)-[1,3]oxazolo[5,4-d]pyrimidine derivatives, process for their preparation and pharmaceutical compositions containing them
PL2770844T3 (en) Tomato derived composition containing enhanced levels of 5'inosine monophosphate
IN2014DN06122A (en)
EP2551266A4 (en) 2',2-dithiazol non-nucleoside compounds, preparation methods, pharmaceutical compositions and uses as hepatitis virus inhibitors thereof
HK1187061A1 (en) Delta crystalline form of the arginine salt of perindopril, a process for its preparation, and pharmaceutical compositions containing it
MA33883B1 (en) The process of formation and crystalline form of hydrochloride 4} 3] c-hexanhydrochlopitan [c] pyrrol-2 (1h)-[yl propoxy {benzamide and the pharmaceutical formulations it contains
MX2013012773A (en) Drug substances, pharmeceutical compositions and methods for preparing the same.
IL228462B (en) Film-forming composition for a ph-dependent sustained release of the active agent
IN2015DN03869A (en)
MX2015011505A (en) Compounds for improved stem cell differentiation into hepatocytes.
MX351994B (en) Crystalline forms of 2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5 -carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino) -ethyl]-amide.